D-Tryptophanol
Need Assistance?
  • US & Canada:
    +
  • UK: +

D-Tryptophanol

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Amino Alcohol
Catalog number
BAT-002608
CAS number
52485-52-6
Molecular Formula
C11H14N2O
Molecular Weight
190.23
D-Tryptophanol
IUPAC Name
(2R)-2-amino-3-(1H-indol-3-yl)propan-1-ol
Synonyms
(R)-2-Amino-3-(3-indolyl)-1-propanolD-Trp-ol
Appearance
White to off-white solid
Purity
≥ 98% (HPLC)
Density
1.245±0.06 g/cm3
Melting Point
75-82 °C
Boiling Point
444.2±30.0 °C(Predicted)
Storage
Store at 2-8 °C
InChI
InChI=1S/C11H14N2O/c12-9(7-14)5-8-6-13-11-4-2-1-3-10(8)11/h1-4,6,9,13-14H,5,7,12H2/t9-/m1/s1
InChI Key
UDQCRUSSQAXPJY-SECBINFHSA-N
Canonical SMILES
C1=CC=C2C(=C1)C(=CN2)CC(CO)N
1. Pharmacological characterization of 3-azabicyclo[3,2,1] octane-1-yl-l-leucyl-d-tryptophanyl-d-4-Cl-phenylalanine: A novel ET(A) receptor-selective antagonist
Xin Li, Ke-Liang Liu, Jian-Quan Zheng, Mu-Gen Chi, Jun-Jun Dong, Si-Jian Dong, Ze-Hui Gong Pulm Pharmacol Ther. 2008 Oct;21(5):780-7. doi: 10.1016/j.pupt.2008.06.001. Epub 2008 Jun 11.
Background and objectives: Pulmonary hypertension is a kind of disease associated with a very high rate of mortality. There are not many effective drugs for the treatment of pulmonary hypertension. Treatment with ET-1 receptor antagonists was proved to be effective in the treatment of pulmonary hypertension. Aiming at developing new endothelin A receptor (ET(A)) antagonist for treatment of pulmonary hypertension, 242 peptide compounds were synthesized by structural optimization of a selective ET(A) receptor antagonist BQ-123. Among these, -azabicyclo[3,2,1]octane-1-yl-l-Leucyl-d-tryptophanyl-d-4-Cl-phenylalanine, named ETP-508, was selected for further harmacological characterization. Methods: Radioligand binding assay was performed to study the binding affinity of ETP-508 for ET(A) and ET(B) receptors. The biological activity of ETP-508 was evaluated in isolated rat aortic ring experiment and in systemic arterial pressure experiment. In addition, hypotensive effect of ETP-508 was investigated on hypoxia-induced pulmonary hypertension. Results: ETP-508 binds to endothelin ET(A) receptor with >10,000-fold higher affinity than to endothelin B receptor in rat lung tissue preparation. ETP-508 inhibited endothelin-1 (ET-1)-induced contraction of isolated rat aortic ring and shifted the cumulative concentration-contraction response curve to ET-1 to right with no change in the maximal response. In vivo, ETP-508 inhibited the increased effect of ET-1 on mean systemic arterial pressure. Pre-treatment with ETP-508 by intravenous infusion significantly inhibited chronic hypoxia-induced pulmonary hypertension and right ventricular hypertrophy. ETP-508 also significantly inhibited the increase in lung ET-1 expression level, hemoglobin, red-cell count and red-cell hematocrit as induced by hypoxia. Furthermore, ETP-508 partially reversed pre-established pulmonary hypertension and right ventricle hypertrophy by chronic hypoxia. Conclusion: These results indicated that ETP-508 is a novel highly selective ET(A) receptor antagonist and may have a great potential to be developed as a drug of anti-pulmonary hypertension.
2. Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target
Young Ha Ahn, Se-Chan Oh, Shengtao Zhou, Tae-Don Kim Int J Mol Sci. 2021 Apr 26;22(9):4523. doi: 10.3390/ijms22094523.
Tryptophanyl-tRNA synthetase (WRS) is an essential enzyme that catalyzes the ligation of tryptophan (Trp) to its cognate tRNAtrp during translation via aminoacylation. Interestingly, WRS also plays physiopathological roles in diseases including sepsis, cancer, and autoimmune and brain diseases and has potential as a pharmacological target and therapeutic. However, WRS is still generally regarded simply as an enzyme that produces Trp in polypeptides; therefore, studies of the pharmacological effects, therapeutic targets, and mechanisms of action of WRS are still at an emerging stage. This review summarizes the involvement of WRS in human diseases. We hope that this will encourage further investigation into WRS as a potential target for drug development in various pathological states including infection, tumorigenesis, and autoimmune and brain diseases.
Online Inquiry
Verification code
Inquiry Basket